NU6102

Overview

NU6102 is a potent CDK1 and CDK2 inhibitor with IC 50 s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3 , respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC 50 of 1.6 μM), DYRK1A (IC 50 of 0.9 μM), PDK1 (IC 50 of 0.8 μM) and ROCKII (IC 50 of 0.6 μM).

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-15569
• CAS No.: 444722-95-6
• Molecular Formula: C18H22N6O3S
• Molecular Weight: 402.47
• Purity: 99.23%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (6.21 mM); Clear solution
• Availability: In-stock

Source

Original product source